Pipeline Market Review on Therapeutic Landscape of Rubella (German measles) H2 2016
No of Pages – 45 Publishing Date - November, 2016 Browse detailed TOC, Tables, Figures and Charts in Global Serial Device Server Consumption 2016 Market Research Report athttp://www.marketresearchhub.com/report/rubella-german-measles-pipeline-review-h22016-report.html
A latest pipeline guide of pharmaceutical and healthcare disease by Global Market Direct has been launched and added to Market Research Hub’s vast partfolio of research reports. The report is titled as “Rubella (German Measles) - Pipeline Review, H2 2016”. This guide evaluates Rubella’s therapeutics development based on mechanism of action (MoA), drug target, monotherapy products, combination products, route of administration (RoA) and molecule type.
The report offers a brief overview about German measles disease and its therapeutic development. It is an infectious disease caused by a virus called “Rubella”. This directly infects the skin and lymph nodes. The main symptom is a pink spotty rash that starts from the face and spreads to the arms & chest. Other symptoms include mild fever, headaches, swollen glands, joint pain and red eyes. German measles is highly infectious to child bearing women during the first trimester of pregnancy. This disease can even cause miscarriage or birth defects. It is generally transmitted by airborne droplets when an infected person coughs or sneezes.
Request A Sample Report
The report further highlights greater focus on effective drug treatment of Rubella. In addition, increasing R&D programs for development of new therapies to successfully treat the disease is expected to favor the market in the near future. According to the study, German measles is extremely rare in the United States. Most of the cases occur in people who live in countries that don’t offer routine immunization against Rubella. Generally, mainstream medicine doesn't have a specific treatment for German measles as it goes away within a week and the mild symptoms can be managed with bed rest and medicines.But the doctors advise pregnant women for virus vaccine immunization to avoid acquiring German measles. A vaccine named measlesmumps-rubella (MMR) can be used to effectively prevent it. The rubella vaccine was introduced in the late 1960s and due to this vaccine the incidence of German measles has significantly declined. Also, a mixture of proteins in the blood called “Gamma globulin” is offered to prevent the disease. The Rubella pipeline guide also review the key players involved in therapeutic development for this infection and also features dormant and discontinued projects. Some of the key players are
Beijing Minhai Biotechnology Co. Biological E. Limited Beijing Tiantan Biological Products GlaxoSmithKline Plc Daiichi Sankyo Company Indian Immunologicals Limited Prometheon Pharma
The guide also helps in identifying emerging players in the market along with their portfolios which enhances decision making capabilities for the new entrants.
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Rubella (German Measles) Overview 6 Therapeutics Development 7 Pipeline Products for Rubella (German Measles) - Overview 7 Pipeline Products for Rubella (German Measles) - Comparative Analysis 8 Rubella (German Measles) - Therapeutics under Development by Companies 9 Rubella (German Measles) - Therapeutics under Investigation by Universities/Institutes 10 Rubella (German Measles) - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Request A Sample Report
Early Stage Products 13 Unknown Stage Products 14 Rubella (German Measles) - Products under Development by Companies 15 Rubella (German Measles) - Products under Investigation by Universities/Institutes 16 Rubella (German Measles) - Companies Involved in Therapeutics Development 17 Beijing Minhai Biotechnology Co., Ltd 17 Beijing Tiantan Biological Products Co., Ltd. 18 Biological E. Limited 19 Daiichi Sankyo Company, Limited 20 GlaxoSmithKline Plc 21 Indian Immunologicals Limited 22 Prometheon Pharma, LLC 23 Sinovac Biotech Ltd. 24 Zydus Cadila Healthcare Limited 25 Rubella (German Measles) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26 Assessment by Combination Products 27 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 (measles + mumps + rubella + varicella) vaccine - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 (measles + mumps + rubella + varicella) vaccine - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 (measles + mumps + rubella) vaccine - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 (measles + mumps + rubella) vaccine - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 (measles + mumps + rubella) vaccine - Drug Profile 36 Product Description 36 Mechanism Of Action 36 Request A Sample Report R&D Progress 36 (measles + rubella + varicella) vaccine - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 (measles + rubella) vaccine - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 (measles + rubella) vaccine - Drug Profile 39 Product Description 39 Mechanism Of Action 39
R&D Progress 39 (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 rubella vaccine - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 VN-0102 - Drug Profile 42 Product Description 42 Mechanism Of Action 42
Ask For Discount R&D Progress 42 Rubella (German Measles) - Dormant Projects 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45 Report Details – Date of Publishing – Nov, 2016 No of Pages – 45 Single User License – $2000 Multiple User License – $4000
Buy Report Now!
About Market Research HUB : Market Research HUB is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments. Contact– 90 State Street, Albany, NY 12207, United States Toll Free : 866-997-4948 (US-Canada) Tel : +1-518-621-2074 Email : sales@marketresearchhub.com Website : http://www.marketresearchhub.com/